FDA inspection
Hanlim Pharm Co. Ltd.: FDA inspection ending Apr 24, 2026
FDA inspection 1313712 · Official Action Indicated (OAI) · Yongin
Key facts
| Inspection ID | 1313712 |
|---|---|
| Firm | Hanlim Pharm Co. Ltd. |
| FEI number | 3004886113 |
| Address | Hallimjeyakjungangyeonguso, 2-27 Yeongmun-Ro; Cheoin |
| City | Yongin |
| Country | Korea (the Republic of) |
| Fiscal year | 2026 |
| Inspection end date | Apr 24, 2026 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 734782 |
At a glance
- 10–99 Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data